Data Presented at ATTD 2014 Suggest t:slim® Insulin Pump Faster to Train with Fewer Use Errors than Competition

SAN DIEGO, Feb. 6, 2014 /PRNewswire/ -- Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the t:slim® Insulin Pump, today presented the results of a research study that demonstrated faster training times and fewer errors when using the t:slim Pump versus a leading insulin pump. These data were presented at the 7^th Annual Advanced Technologies and Treatments for Diabetes (ATTD) International Conference in Vienna, Austria.

(Logo: http://photos.prnewswire.com/prnh/20131220/LA37333LOGO)

"Extensive human factors research went into the development of the t:slim Insulin Pump's intuitive touch screen user interface," said Kim Blickenstaff, president and CEO of Tandem Diabetes Care. "We believe the shorter training times and reduced use errors observed in this study are a testament to the importance of this kind of research in medical device development."

The multi-center study looked at usability differences and training times for seven of the most common tasks performed on an insulin pump.  Participants had never used an insulin pump before, and were using multiple daily injections of insulin for their current therapy (n=72).  Subjects were randomized to train on either the t:slim Insulin Pump or the Medtronic® MiniMed® Paradigm Revel™ Insulin Pump. On the first visit of the study, participants were trained by a diabetes educator from the study site.  On the second visit, which took place 24 to 48 hours later, participants performed the seven tasks without assistance. Study participants did not have access to the pump between visits.  On average, the t:slim Pump took 27 percent less time to train than the Revel Pump (17.6 minutes vs. 24.1 minutes). The same users also experienced 65 percent fewer task failures (0.8 errors vs. 2.3 errors).  A survey was administered at the end of the second visit to evaluate different aspects of the pump and training.  Results showed that compared to the Revel Pump, the t:slim Pump used terminology that was easier to understand, had a screen with better contrast, was easier to read, was a better size, was easier to program, and was more enjoyable to use.

In another presentation at ATTD, data was presented from a preliminary analysis of self-reported outcomes of people using the t:slim Insulin Pump.  A subset of t:slim Pump users self-reported their HbA1c, a three-month average blood glucose measurement (n=289).  t:slim Pump users who had previously used a different insulin pump (n=211) saw an HbA1c decrease of 0.2 percentage points (p< 0.001, average t:slim Pump use approximately 6 months). People who had never used an insulin pump before (n=78), reported an HbA1c decrease of 0.9 percentage points (p<0.001, average t:slim Pump use approximately 5 months).

These data were presented as part of the Tandem-sponsored symposium, Optimizing Insulin Pump Use through Human Factors Research, moderated by Dr. Timothy Bailey. Human Factors Research is a scientific discipline that uses evidence-based data to optimize a device or system to the intended user through iterative usability testing and design refinement. Tandem's t:slim Pump was one of the first insulin pumps to use extensive Human Factors Research in its development.  It is the first insulin pump with a color touch screen, rechargeable battery, and USB-connectivity, and it holds up to 300 units of insulin.

About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical device company with an innovative, user-centric and integrated approach to the design, development and commercialization of products for people with insulin-dependent diabetes. The Company manufactures and sells the t:slim Insulin Pump, the slimmest and smallest durable insulin pump currently on the market, and the first and only insulin pump with a high resolution, color touch screen. Tandem is based in San Diego, California.

Forward Looking Statement
This press release includes forward-looking statements relating to Tandem's t:slim® Insulin Pump, including the results and conclusions from research studies comparing the t:slim Pump to other currently marketed insulin pumps, and the properties and potential benefits of using the t:slim Pump as compared to multiple daily injections. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including: risks that current and past results of research studies may not be indicative of results of future research studies or of actual user experience; the potential that newer products that compete with the t:slim Pump, or other technological breakthroughs for the monitoring, treatment or prevention of diabetes, may render the t:slim Pump obsolete or less desirable; Tandem's ability to manufacture products in commercial quantities at an acceptable cost and while maintaining quality standards;  and other risks identified in Tandem's Registration Statement on Form S-1. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Tandem undertakes no obligation to update any forward-looking statement in this press release.

Follow Tandem Diabetes Care on Twitter @tandemdiabetes, use #tslim and #tconnect.
Follow Tandem Diabetes Care on Facebook at www.facebook.com/TandemDiabetes.

t:slim, t:connect and Tandem Diabetes Care are registered trademarks of Tandem Diabetes Care, Inc. Medtronic and Minimed are registered trademarks, and Revel is a trademark, of Medtronic, Inc.

SOURCE Tandem Diabetes Care, Inc.